The global live cell encapsulation technology market is estimated to grow at a high rate during the forecast period. A number of factors such as increasing incidence of various types of cancers (such as pancreatic, breast, and brain), rising prevalence of diabetes, and rising adoption of cell encapsulation technology to develop treatments for cancer and diabetes are fuelling the growth of the global live cell encapsulation technology market.
However, lack of clinical-grade polymers; production of uniform capsules; ethical, political, and regulatory issues; and other technological and biological limitations are some of the major challenges that needs to be overcome by the key players to sustain in this market.
Cell encapsulation technology enables to overcome the existing issue of graft rejection in tissue engineering applications. It helps to minimize the requirement for long-term use of immuno-suppressive drugs after an organ transplant in order to control side effects. This technology is also known as Cell-in-a-Box. It enables to encapsulate cells in cellulose based, beads, with a semipermeable membrane that allow nutrients and waste product exchange, however, retains the cells within the beads. Cell-in-a-Box has been showing great promise in the areas of diabetes, cancer, and research associated with drug delivery.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218019375
Austrianova Singapore Pte Ltd (Singapore), Beta-Cell NV (Belgium), Cellmed AG (Germany), Cerco Medical (U.S.), Living Cell Technologies Limited (New Zealand), Neurotech Pharmaceuticals, Inc. (Rhode Island), NovaMatrix (Norway), PharmaCyte Biotech, Inc. (Maryland), Sigma-Aldrich Co. LLC. (U.S.), and ViaCyte, Inc. (U.S.) are some of the key players in the global live cell encapsulation technology market. Market players primarily focus on the development of novel encapsulation technologies and inorganic strategies such as acquisitions and agreements in order to ensure their growth in this market.
News-Dive-Press 